Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib vs placebo in polymyalgia rheumatica
ChiCTR2500105703Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Ivarmacitinib arm with Placebo arm (2 arms). Primary endpoint: PMR-AS score. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on ChiCTR2500105703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105703.